The clinical information you need, at your fingertips.

Medical News for You

Cell

28m

Younger adults with colorectal, breast cancer show distinct gut bacteria

The gut microbes patients carried before treatment tracked with how long they survived and who developed diarrhea during chemotherapy. . .

EASD 2026

Wegovy pill after injections: What happens to weight?

Study found a 4.1% reduction over three months among patients who stayed on treatment. . .

Drug pipeline

Tulisokibart delivers first positive anti-TL1A phase 2 results in hidradenitis suppurativa

Investigational therapy showed improvements in disease activity and quality of life in a condition with persistent unmet treatment needs. . .

EASD 2026

Trevogrumab cuts semaglutide-associated lean mass loss by about half

Investigational anti-myostatin therapy improved body composition in adults with obesity receiving semaglutide. . .

J Clin Oncol

Fills of oral blood cancer drugs fall as out-of-pocket costs rise

Approved prescriptions went unfilled far more often when patients faced the highest out-of-pocket costs, and most first submissions to insurers were rejected. . .

Company news

Recarbrio discontinued from US market

Merck says the withdrawal is unrelated to safety or effectiveness concerns; alternative treatments for multidrug-resistant Gram-negative infections remain available. . .

EADV 2026

10h

Are GLP-1 drugs affecting patients’ nails?

Nail detachment and discoloration were markedly more common among GLP-1 receptor agonist users than matched controls. . .

Lancet Reg Health Am

12h

EASD 2026: Half of young adults with T2D achieved remission with diet-plus-exercise program

Intensive calorie restriction paired with structured exercise produced high remission rates while preserving muscle mass. . .

EASD 2026

Eloralintide boosts tirzepatide weight loss to 23% in T2D

Adding a selective amylin receptor agonist to the highest incretin dose led to greater weight loss and larger A1C reductions versus incretin alone. . .